Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies

Activation of PDGFRA by genomic aberrations contributes to tumor progression in several tumor types. Here, the authors perform functional characterization of 16 novel PDGFRA mutations identified from different tumor types and demonstrate that a neomorphic PDGFRA extracellular domain driver mutation...

Full description

Bibliographic Details
Main Authors:	Carman K. M. Ip, Patrick K. S. Ng, Kang Jin Jeong, S. H. Shao, Zhenlin Ju, P. G. Leonard, Xu Hua, Christopher P. Vellano, Richard Woessner, Nidhi Sahni, Kenneth L. Scott, Gordon B. Mills
Format:	Article
Language:	English
Published:	Nature Publishing Group 2018-11-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-018-06949-w

id	doaj-5afbb5f4318a4d348864297344880429
record_format	Article
spelling	doaj-5afbb5f4318a4d3488642973448804292021-05-11T09:52:45ZengNature Publishing GroupNature Communications2041-17232018-11-019111410.1038/s41467-018-06949-wNeomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapiesCarman K. M. Ip0Patrick K. S. Ng1Kang Jin Jeong2S. H. Shao3Zhenlin Ju4P. G. Leonard5Xu Hua6Christopher P. Vellano7Richard Woessner8Nidhi Sahni9Kenneth L. Scott10Gordon B. Mills11Department of Systems Biology, The University of Texas MD Anderson Cancer CenterSheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer CenterDepartment of Systems Biology, The University of Texas MD Anderson Cancer CenterSheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer CenterDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer CenterInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer CenterDepartment of Systems Biology, The University of Texas MD Anderson Cancer CenterCenter for Co-Clinical Trials, The University of Texas MD Anderson Cancer CenterCancer Bioscience, in vivo Cancer Pharmacology, AstraZeneca PhamaceuticalsDepartment of Systems Biology, The University of Texas MD Anderson Cancer CenterDan L. Duncan Cancer Center, Baylor College of MedicineDepartment of Systems Biology, The University of Texas MD Anderson Cancer CenterActivation of PDGFRA by genomic aberrations contributes to tumor progression in several tumor types. Here, the authors perform functional characterization of 16 novel PDGFRA mutations identified from different tumor types and demonstrate that a neomorphic PDGFRA extracellular domain driver mutation is resistant to PDGFRA targeted therapies.https://doi.org/10.1038/s41467-018-06949-w
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Carman K. M. Ip Patrick K. S. Ng Kang Jin Jeong S. H. Shao Zhenlin Ju P. G. Leonard Xu Hua Christopher P. Vellano Richard Woessner Nidhi Sahni Kenneth L. Scott Gordon B. Mills
spellingShingle	Carman K. M. Ip Patrick K. S. Ng Kang Jin Jeong S. H. Shao Zhenlin Ju P. G. Leonard Xu Hua Christopher P. Vellano Richard Woessner Nidhi Sahni Kenneth L. Scott Gordon B. Mills Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies Nature Communications
author_facet	Carman K. M. Ip Patrick K. S. Ng Kang Jin Jeong S. H. Shao Zhenlin Ju P. G. Leonard Xu Hua Christopher P. Vellano Richard Woessner Nidhi Sahni Kenneth L. Scott Gordon B. Mills
author_sort	Carman K. M. Ip
title	Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
title_short	Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
title_full	Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
title_fullStr	Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
title_full_unstemmed	Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
title_sort	neomorphic pdgfra extracellular domain driver mutations are resistant to pdgfra targeted therapies
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2018-11-01
description	Activation of PDGFRA by genomic aberrations contributes to tumor progression in several tumor types. Here, the authors perform functional characterization of 16 novel PDGFRA mutations identified from different tumor types and demonstrate that a neomorphic PDGFRA extracellular domain driver mutation is resistant to PDGFRA targeted therapies.
url	https://doi.org/10.1038/s41467-018-06949-w
work_keys_str_mv	AT carmankmip neomorphicpdgfraextracellulardomaindrivermutationsareresistanttopdgfratargetedtherapies AT patrickksng neomorphicpdgfraextracellulardomaindrivermutationsareresistanttopdgfratargetedtherapies AT kangjinjeong neomorphicpdgfraextracellulardomaindrivermutationsareresistanttopdgfratargetedtherapies AT shshao neomorphicpdgfraextracellulardomaindrivermutationsareresistanttopdgfratargetedtherapies AT zhenlinju neomorphicpdgfraextracellulardomaindrivermutationsareresistanttopdgfratargetedtherapies AT pgleonard neomorphicpdgfraextracellulardomaindrivermutationsareresistanttopdgfratargetedtherapies AT xuhua neomorphicpdgfraextracellulardomaindrivermutationsareresistanttopdgfratargetedtherapies AT christopherpvellano neomorphicpdgfraextracellulardomaindrivermutationsareresistanttopdgfratargetedtherapies AT richardwoessner neomorphicpdgfraextracellulardomaindrivermutationsareresistanttopdgfratargetedtherapies AT nidhisahni neomorphicpdgfraextracellulardomaindrivermutationsareresistanttopdgfratargetedtherapies AT kennethlscott neomorphicpdgfraextracellulardomaindrivermutationsareresistanttopdgfratargetedtherapies AT gordonbmills neomorphicpdgfraextracellulardomaindrivermutationsareresistanttopdgfratargetedtherapies
_version_	1721449053974167552

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies

Similar Items